What does this research mean for the field?

Nivolumab therapy can induce acute tubulointerstitial nephritis in patients being treated for gastric cancer. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To report a case of acute tubulointerstitial nephritis associated with nivolumab treatment in a gastric cancer patient.

May 3, 2026SHILAP Revista de lepidopterología0 citationsOpen Access

View Full Paper

Nivolumab-Associated Acute Tubulointerstitial Nephritis in a Gastric Cancer Patient

EOEngin OnanBaşkent University TCTuba CanpolatBaşkent University DTDi̇lek TorunBaşkent University

Key Points

To report a case of acute tubulointerstitial nephritis associated with nivolumab treatment in a gastric cancer patient.
Descriptive case report of a gastric cancer patient treated with nivolumab.
Clinical assessment of renal function and histological evaluation of kidney biopsy.
Patient developed acute kidney injury and diagnostic biopsy confirmed acute tubulointerstitial nephritis.
Nivolumab was identified as the likely causative agent for the renal condition.

Abstract

Cite this article as: Onan E, Canpolat T, Torun D, Kozanoglu R, Micozkadioglu H, Kose F. Nivolumab-associated acute tubulointerstitial nephritis in a gastric cancer patient. Turk J Nephrol. 2025;34(4):314-315.

Demander à l'IA

Bookmark

View Full Paper

Demander à l'IA

Bookmark

View Full Paper

Nivolumab-Associated Acute Tubulointerstitial Nephritis in a Gastric Cancer Patient

Key Points

Abstract

Cite This Study